Zamtocabtagene Autoleucel (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 as a Potential Treatment Option for Patients with Relapsed/ Refractory B Cell Non-Hodgkin Lymphoma
Presenting at the European Hematology Association (EHA) 2022 Congress, Peter Borchmann from the University of Cologne, Germany…